Publicaciones - IR Sant Pau

Buscar

01/03/2026 Clinical and Economic Implications of Immunoglobulin Use Under Restrictive Conditions in Adult Patients With Neurological Diseases and Immunodeficiencies in Spain

Querol, L, Montoro-Ronsano, JB, Soler-Palacín, P, Galduf, J, Martínez-Pérez, O, Díaz-Cuervo, H. Clinical and Economic Implications of Immunoglobulin Use Under Restrictive Conditions in Adult Patients With Neurological Diseases and Immunodeficiencies in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2026; 33(3)DOI:10.1111/ene.70570. PMID:41834317. IF:3.900(Q1/3D).

28/04/2026 Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies

Roy, B, Obaid, AH, Wang, ZJ, Kovacs, KG, Ohashi, S, Kalayci, FNC, Joo, D, Masi, G, Coppola, C, Das, S, Hernandez, AL, Martin-Aguilar, L, Lleixà, C, Nowak, RJ, Querol, L, O'Connor, KC. Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2026; 123(17)DOI:10.1073/pnas.2525717123. PMID:42008666. IF:9.100(Q1/2D).

01/04/2026 Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease

Bermejo-Guerrero, L, Restrepo-Vera, JL, Martin-Jimenez, P, Navarro-Riquelme, M, Garrido-Moraga, R, Ochoa, LE, González-Quintana, A, Hernandez-Lain, A, Castillo-Villalba, J, Morís, G, Muelas, N, García-Arumí, E, González, V, Martínez-Sáez, E, Vesperinas, A, Llansó, L, Juntas-Morales, R, Paradas, C, Kapetanovic, S, Blázquez, A, Martí, R, Arenas, J, Martín, MA, Domínguez-González, C. Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease. Neurology-Genetics. 2026; 12(2)DOI:10.1212/NXG.0000000000200365. PMID:41822038. IF:3.700(Q1/3D).

09/03/2026 Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease

Claramunt-Molet, M, Pegueroles, J, Pi-Cervera, A, Rico, M, Idelsohn-Zielonka, S, Domínguez-González, C, Corti, M, Antón, V, Salabarria, SM, Wong, K, James, MK, Byrne, BJ, Díaz-Manera, J. Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease. Journal of NeuroEngineering and Rehabilitation. 2026; 23(1)DOI:10.1186/s12984-026-01898-8. PMID:41803906. IF:5.200(Q1/1D).

20/04/2026 Connecting HTT intermediate alleles and microRNA dysregulation to enhanced tauopathy in late-onset Alzheimer's disease

Castilla-Silgado, J, Perez-Oliveira, S, Pinto-Hernandez, P, Fernandez-Sanjurjo, M, Corte-Torres, MD, Fernandez-Alvarez, O, Iglesias-Gutierrez, E, Menendez-Gonzalez, M, Alvarez, V, Tomas-Zapico, C. Connecting HTT intermediate alleles and microRNA dysregulation to enhanced tauopathy in late-onset Alzheimer's disease. Alzheimers Research & Therapy. 2026; 18(1)DOI:10.1186/s13195-026-02039-y. PMID:42010634. IF:7.600(Q1/1D).

01/04/2026 Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs

Cortés-Vicente, E, Casasnovas, C, Juntas, R, Sevilla, T, Pardo, J, de Rivera, FR, Sola, AG. Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs. NEUROLOGIA. 2026; 41(3)DOI:10.1016/j.nrl.2025.501912. PMID:. IF:3.100(Q2/4D).

14/03/2024 Cognitive disorders in advanced Parkinson's disease: challenges in the diagnosis of delirium

Daniels, C, Rodriguez-Antigueedad, J, Jentschke, E, Kulisevsky, J, Volkmann, J. Cognitive disorders in advanced Parkinson's disease: challenges in the diagnosis of delirium. Neurological Research And Practice. 2024; 6(1)DOI:10.1186/s42466-024-00309-4. PMID:38481336. IF:(Q/D).

01/10/2022 Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium

Sexton, C, Solis, M, Aharon-Peretz, J, Alexopoulos, P, Apostolova, LG, Bayen, E, Birkenhager, B, Cappa, S, Constantinidou, F, Fortea, J, Gerritsen, DL, Hassanin, HI, Ibanez, A, Ioannidis, P, Karageorgiou, E, Korczyn, A, Leroi, I, Lichtwarck, B, Logroscino, G, Lynch, C, Mecocci, P, Molinuevo, JL, Papatriantafyllou, J, Papegeorgiou, S, Politis, A, Raman, R, Ritchie, K, Sanchez-Juan, P, Sano, M, Scarmeas, N, Spiru, L, Stathi, A, Tsolaki, M, Yener, G, Zaganas, I, Zygouris, S, Carrillo, M. Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. ALZHEIMERS & DEMENTIA. 2022; 18(10)DOI:10.1002/alz.12588. PMID:35184367. IF:14.000(Q1/1D).

03/08/2024 Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

Verberk, IMW, Jutte, J, Kingma, MY, Vigneswaran, S, Gouda, MMTEE, van Engelen, MP, Alcolea, D, Arranz, J, Fortea, J, Lleó, A, Chevalier, C, Marizzoni, M, van de Giessen, EM, Lemstra, AW, Pijnenburg, YAL, van der Flier, WM, den Braber, A, Wilson, D, Schut, MC, van Harten, AC, Teunissen, CE. Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. ALZHEIMERS & DEMENTIA. 2024; 20(9)DOI:10.1002/alz.14088. PMID:39096164. IF:11.100(Q1/1D).

20/03/2024 Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium

Larsen, FK, Baksh, RA, Mcglinchey, E, Langballe, EM, Benejam, B, Beresford-Webb, J, Mccarron, M, Coppus, A, Falquero, S, Fortea, J, Levin, J, Loosli, SV, Mark, R, Rebillat, AS, Zaman, S, Strydom, A. Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium. ALZHEIMERS & DEMENTIA. 2024; 20(5)DOI:10.1002/alz.13779. PMID:38506627. IF:11.100(Q1/1D).

01/01/2024 Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry

Lugogo, NL, Heffler, E, Plaza, V, Hilberg, O, Xia, CM, Nash, S, Pandit, N, Jacob-Nara, JA, Sacks, HJ, Rowe, PJ, Deniz, Y, Hardin, M, Soler, X. Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry. Journal of Asthma and Allergy. 2024; 17DOI:10.2147/JAA.S451689. PMID:38860029. IF:3.000(Q2/4D).

02/01/2024 Disparities in Coronavirus Disease 2019 Clinical Outcomes and Vaccination Coverage Among Migrants With Human Immunodeficiency Virus in the PISCIS Cohort: A Population-Based Propensity Score-Matched Analysis

Nomah, DK, Díaz, Y, Bruguera, A, Moreno-Fornés, S, Aceiton, J, Reyes-Urueña, J, Llibre, JM, Falcó, V, Imaz, A, Fanjul, FJ, Peraire, J, Deig, E, Domingo, P, Inciarte, A, Casabona, J, Miró, JM. Disparities in Coronavirus Disease 2019 Clinical Outcomes and Vaccination Coverage Among Migrants With Human Immunodeficiency Virus in the PISCIS Cohort: A Population-Based Propensity Score-Matched Analysis. Open Forum Infectious Diseases. 2024; 11(1)DOI:10.1093/ofid/ofad693. PMID:38221982. IF:3.800(Q1/3D).

04/12/2025 BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes

Johnatty, SE, Tudini, E, Parsons, MT, Michailidou, K, Zanti, M, Canson, DM, Davidson, AL, Berger, T, Rosti, RO, Kratz, CP, Kalb, R, McReynolds, LJ, Giri, N, Richardson, ME, Pesaran, T, Surrallés, J, Pujol, R, Vundinti, BR, George, M, Maxwell, KN, Nathanson, K, Domchek, S, Fiesco-Roa, MO, Frias, S, Garcia-de-Teresa, B, Jongmans, M, Lalani, S, Maiburg, M, Prescott, K, Robinson, R, Rajagopalan, S, Blok, LS, Temple, SEL, Tucker, K, Auerbach, AD, Cancio, MI, Kennedy, JA, MacMillan, ML, Tryon, R, Wagner, JE, Walsh, M, Boddicker, NJ, Hu, CL, Weitzel, JN, Dingemans, AJM, Hadler, J, Rotenberg, N, Ramadane-Morchadi, L, de la Hoya, M, James, P, Hansen, TV, Vreeswijk, MPG, Walker, LC, Sharan, SK, Easton, DF, Couch, F, Smogorzewska, A, Nelson, A, Ngeow, J, Tischkowitz, M, Gomez-Garcia, E, Spurdle, AB. BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes. AMERICAN JOURNAL OF HUMAN GENETICS. 2025; 112(12)DOI:10.1016/j.ajhg.2025.10.007. PMID:41172994. IF:8.100(Q1/1D).

01/08/2025 Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study

García-Alfonso, P, Jimenez-Fonseca, P, Soto-Alsar, J, Baraibar, I, Santos, C, La Casta, A, Ghanem, I, Cortijo, G, Méndez, A, Pazo-Cid, R, Vera, R, Melián, M, Alcaide, J, Graña, B, Páez, D, Gallego, I, Lobo, M, Borregón, M, Montes, A, de Castro, E, Carmona-Bayonas, A, Aranda, E. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. ONCOLOGIST. 2025; 30(8)DOI:10.1093/oncolo/oyae300. PMID:39550209. IF:4.200(Q2/3D).

01/12/2024 Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

García-Alfonso, P, Elez, E, Soto-Alsar, J, Páez, D, Fernández-Montes, A, Graña, B, Salud, A, Yubero, A, Gómez-España, MA, Macías, I, Quintero, G, López-López, C, Fernández-Rodríguez, T, Grávalos, C, González-Flores, E, Guix, M, Paredes, BG, Reina, JJ, Mowbray, JRR, Sastre, J, Aranda, E. Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 2024; 9(12)DOI:10.1016/j.esmoop.2024.103986. PMID:39608305. IF:8.300(Q1/2D).

21/04/2024 Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI

Aranha, MR, Montal, V, van den Brink, H, Pegueroles, J, Carmona-Iragui, M, Videla, L, Blesa, LM, Benejam, B, Arranz, J, Valldeneu, S, Barroeta, I, Fernández, S, Ribas, L, Alcolea, D, González-Ortiz, S, Bargalló, N, Biessels, GJ, Blesa, R, Lleó, A, Coutinho, AM, Leite, CC, Bejanin, A, Fortea, J. Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI. ALZHEIMERS & DEMENTIA. 2024; 20(6)DOI:10.1002/alz.13797. PMID:38644660. IF:11.100(Q1/1D).

01/08/2024 Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations

Muñoz-Casares, FC, Martín-Broto, J, Cascales-Campos, P, Torres-Melero, J, López-Rojo, I, Gómez-Barbadillo, J, González-Bayón, L, Sebio, A, Serrano, C, Carvalhal, S, de Souza, JA, Souza, A, Flores-Ayala, G, Fuenmayor, LJP, Lopes-Bras, R, González-López, JA, Vasques, H, Asencio-Pascual, JM. Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations. Cancers. 2024; 16(15)DOI:10.3390/cancers16152646. PMID:39123374. IF:4.400(Q2/3D).

01/03/2026 Central nervous system disorders following haematopoietic stem cell transplantation: a prospective case-control observational study from the Infectious Diseases Working Party and the Transplant Complications Working Party of EBMT

Schmidt-Hieber, M, Ljungman, P, Gilbert, P, Knelange, N, Drozd-Sokolowska, J, Basak, G, Einsele, H, Tridello, G, Abdeljelil, NB, Kulagin, A, Balaguer-Rosello, A, Metafuni, E, Faraci, M, Gozdzik, J, Martino, R, Raiola, AM, Xhaard, A, Kuskonmaz, B, Biffi, A, Czyzewski, K, Gabriel, MA, Martínez-Lopez, J, Zaidman, I, Schlegel, PG, Gruhn, B, Krivan, G, Vicent, MG, Mikulska, M, Peric, Z, Averbuch, D, Styczynski, J, Penack, O, de la Camara, R. Central nervous system disorders following haematopoietic stem cell transplantation: a prospective case-control observational study from the Infectious Diseases Working Party and the Transplant Complications Working Party of EBMT. Eclinicalmedicine. 2026; 93DOI:10.1016/j.eclinm.2026.103792. PMID:41783087. IF:10.000(Q1/1D).

01/02/2026 Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Döhner, H, Schuh, AC, Recher, C, O'Nions, J, Aldoss, I, Piérola, AA, Allred, AJ, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Daskalakis, N, Della Porta, MG, D'Souza, A, Dugan, J, Esteve, J, Fathi, AT, Ferrante, L, Gaj, S, Garciaz, S, Diaz, AG, Salamero, O, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Paniagua, SG, Sackey, N, Sauer, T, Shastri, PN, Searle, E, Tovar, N, Trancucci, D, Vallet, N, Vaughan, L, Vyas, P, Wei, AH, Rölling, C. Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).

24/03/2026 Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups

Rivera-Pérez, C, Morgades, M, Alonso-Saladrigues, A, Montesinos, P, Murciano, T, Gil, C, Adán, R, Esteve, J, Fuentes, C, Amigo, ML, González-Martínez, B, Coll, R, Dapena, JL, De Llano, MPQ, Fuster, JL, García-Cadenas, I, Tasso, M, Barba, P, Rives, S, Ribera, JM. Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups. ANNALS OF HEMATOLOGY. 2026; 105(4)DOI:10.1007/s00277-026-06956-8. PMID:41874722. IF:2.400(Q2/5D).

13/03/2026 Unveiling CMV Risk Signatures After Allogeneic Stem Cell Transplantation Through Machine Learning Approaches: A Multicenter Analysis From the GETH-TC

Giménez, E, Rodriguez-Belenguer, P, Solano, C, Vázquez, L, Martino, R, de la Cámara, R, Rovira, M, Espigado, I, Calvo, CM, López-Jiménez, J, Pérez, A, Bermúdez, A, Saldaña, R, Heras, I, González-Huerta, AJ, Torrado, T, Bautista, G, Perera-Alvarez, MD, González-Pinedo, L, Barba, P, Cuesta, MA, Chorao, P, Basalobre, P, Navarro, D, García-Cadenas, I, Piñana, JL. Unveiling CMV Risk Signatures After Allogeneic Stem Cell Transplantation Through Machine Learning Approaches: A Multicenter Analysis From the GETH-TC. JOURNAL OF MEDICAL VIROLOGY. 2026; 98(3)DOI:10.1002/jmv.70867. PMID:41823077. IF:4.600(Q1/1D).

01/02/2026 Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis

Lopez-Pereira, P, Domínguez, SR, Martin-Moro, F, Caballero, AC, García, AL, Benito, BD, Sarto, MF, Vicente, FD, Marín, JL, Marino, SP, Jiménez-Ubieto, A, Cabirta, A, Gutiérrez, NC, Chulvi, MJL, Puyuelo, A, Prat, AM, Coello, AP, García-Lerma, E, Vilchez, SM. Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis. BONE MARROW TRANSPLANTATION. 2026; 61(2)DOI:10.1038/s41409-025-02772-2. PMID:41310181. IF:5.200(Q1/1D).

01/03/2026 Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects

Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Espinàs, JA, Borras, JM. Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04022-9. PMID:40900393. IF:2.500(Q3/6D).

01/03/2026 Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia

Mecklenbrauck, R, Ramiro, AV, Sträng, E, Gabdoulline, R, Elicegui, JM, Sobas, M, Pleyer, L, Turki, A, Voso, MT, Benner, A, Hernández-Sánchez, A, Tettero, JM, Gimenez, LT, Metzeler, KH, Oñate, G, Lehmann, S, Huntly, BJP, Thomas, I, Thol, FR, Heidel, FH, Valk, PJM, Döhner, K, Haferlach, T, Mills, KI, Döhner, H, Castellani, G, Ossenkoppele, GJ, Hernández-Rivas, JM, Bullinger, L, Heuser, M. Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. LEUKEMIA. 2026; 40(3)DOI:10.1038/s41375-026-02874-w. PMID:41663622. IF:13.400(Q1/1D).

01/02/2026 Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma

Westin, J, Chavez, JC, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, García-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).

01/03/2026 The precision of a report on precision

Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Piñol, JAE, Borras, JM. The precision of a report on precision. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-026-04219-6. PMID:41610006. IF:2.500(Q3/6D).

01/06/2023 Prehospital care process and hospital outcomes in stroke-code cases: comparison of basic and advance life support ambulance attendance

Munoz, SS, Campillo, MDE, Borrega, CS, Azeli, Y, Gil, SQ, Ruiz, A, Albacete, G, Peral, OM, Lluch, S, Delgado, SA, Blas, YS, Urra, X, Calderon, DC, Fabregas, JM, Jacobi, MR, Portela, PC, Garcia, FP, Oller, ED, Benitez, VH, Flores, A, Rubiera, M, Palomeras, E, Garcia-Tornel, A, Soler, RS, Roquet, DV, Salvat-Plana, M, Pachon, AR, Herrero, NPD, Fabrega, XJ. Prehospital care process and hospital outcomes in stroke-code cases: comparison of basic and advance life support ambulance attendance. EMERGENCIAS. 2023; 35(3)DOI:. PMID:37350599. IF:5.400(Q1/1D).

27/09/2024 Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations

Kulisevsky, J, Ferraz, HB, Suppa, A, Reichmann, H. Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations. EUROPEAN NEUROLOGY. 2024; 87(5-6)DOI:10.1159/000541362. PMID:39342935. IF:2.400(Q3/6D).

07/02/2024 Combining mindfulness and cognitive training in children with attention deficit hyperactivity disorder: study protocol of a pilot randomized controlled trial (the NeuroMind study)

Badia-Aguarón, T, Royuela-Colomer, E, Pera-Guardiola, V, Vergés-Balasch, P, Cebolla, A, Luciano, JV, Soler, J, Feliu-Soler, A, Miguel, AH. Combining mindfulness and cognitive training in children with attention deficit hyperactivity disorder: study protocol of a pilot randomized controlled trial (the NeuroMind study). Frontiers in Psychology. 2024; 15DOI:10.3389/fpsyg.2024.1291198. PMID:38384348. IF:2.900(Q1/3D).

01/10/2024 Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study

Feliu-Soler, A, Royuela-Colomer, E, Navarrete, J, Jorgensen, NN, Mariño, M, Demarzo, M, Soler, J, García-Campayo, J, Montero-Marín, J, Luciano, JV. Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study. Journal of Happiness Studies. 2024; 25(7)DOI:10.1007/s10902-024-00820-0. PMID:. IF:3.300(Q1/1D).

01/10/2022 Characteristics of subjective cognitive decline associated with amyloid positivity

Janssen, O, Jansen, WJ, Vos, SJB, Boada, M, Parnetti, L, Gabryelewicz, T, Fladby, T, Molinuevo, JL, Villeneuve, S, Hort, J, Epelbaum, S, Lleo, A, Engelborghs, S, van der Flier, WM, Landau, S, Popp, J, Wallin, A, Scheltens, P, Rikkert, MO, Snyder, PJ, Rowe, C, Chetelat, G, Ruiz, A, Marquie, M, Chipi, E, Wolfsgruber, S, Heneka, M, Boecker, H, Peters, O, Jarholm, J, Rami, L, Tort-Merino, A, Binette, AP, Poirier, J, Rosa-Neto, P, Cerman, J, Dubois, B, Teichmann, M, Alcolea, D, Fortea, J, Sanchez-Saudinos, MB, Ebenau, J, Pocnet, C, Eckerstrom, M, Thompson, L, Villemagne, V, Buckley, R, Burnham, S, Delarue, M, Freund-Levi, Y, Wallin, AK, Ramakers, I, Tsolaki, M, Soininen, H, Hampel, H, Spiru, L, Tijms, B, Ossenkoppele, R, Verhey, FRJ, Jessen, F, Visser, PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. ALZHEIMERS & DEMENTIA. 2022; 18(10)DOI:10.1002/alz.12512. PMID:34877782. IF:14.000(Q1/1D).

13/03/2024 Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome

Hillerstrom, H, Fisher, R, Janicki, MP, Chicoine, B, Christian, BT, Esbensen, A, Esralew, L, Fortea, J, Hartley, S, Hassenstab, J, Keller, SM, Krinsky-McHale, S, Lai, FRC, Levin, J, Mccarron, M, Mcdade, E, Rebillat, AS, Rosas, HD, Silverman, W, Strydom, A, Zaman, SH, Zetterberg, H. Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2024; 20(5)DOI:10.1002/alz.13778. PMID:38480678. IF:11.100(Q1/1D).

01/03/2026 Subphenotype-and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials

Escrihuela-Vidal, F, Larrauri, JG, López-Contreras, J, Euba, G, Vázquez, A, Gómez-Zorrilla, S, López-Cortés, LE, Gasch, O, Aparicio-Minguijón, E, Escudero-Sànchez, R, Pérez-Rodríguez, MT, Rodríguez-Pardo, D, Jover-Sáenz, A, García-Pardo, G, Rodríguez-Baño, J, Pujol, M, Carratalà, J, Gutiérrez-Gutiérrez, B. Subphenotype-and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials. Lancet Regional Health-Europe. 2026; 62DOI:10.1016/j.lanepe.2026.101611. PMID:41788427. IF:13.000(Q1/1D).

15/02/2026 Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials

Escrihuela-Vidal, F, Ong, SWX, Oriol, I, Grillo, S, Pujol, M, Pallarès, N, Tebé, C, Liu, K, Miro, JM, Tong, SYC, Carratalà, J. Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials. CLINICAL INFECTIOUS DISEASES. 2026; 82(2)DOI:10.1093/cid/ciaf387. PMID:40670317. IF:7.300(Q1/1D).

01/02/2026 The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review

Di Bello, F, Gallioli, A, Pecoraro, A, Prudhomme, T, Piana, A, Marco, BB, Haberal, HB, Dönmez, MI, Lopez-Abad, A, Cannoletta, D, Mancon, S, Guirado, L, Facundo, C, Kanashiro, AK, Gavrilov, P, Rodriguez-Faba, O, Gaya, JM, Breda, A, Territo, A. The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review. Minerva Urology And Nephrology. 2026; 78(1)DOI:10.23736/S2724-6051.25.06559-0. PMID:41697205. IF:4.200(Q1/2D).

01/02/2026 Risk factors associated with inadequacy of empirical treatment in patients with sepsis and bacteremia attended in an emergency department

Motos-Bescós, M, Ruiz-Ramos, J, Agra-Montava, I, Moliné-Pareja, A, Palacio-Alvarez, P, Villarejo-Jiménez, A, Pomar-Solchaga, V. Risk factors associated with inadequacy of empirical treatment in patients with sepsis and bacteremia attended in an emergency department. Revista Espanola de Quimioterapia. 2026; 39(1)DOI:10.37201/req/101.2025. PMID:41521957. IF:2.200(Q3/6D).

01/12/2024 Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria

Rubinan, P, Viñado, B, Fernández-Hidalgo, N, Larrosa, N, Sempere, A, Campany, D, Rodríguez-Pardo, D, González-López, JJ, Nuvials, X, del Barrio-Tofiño, E, Escolà-Vergé, L, Los-Arcos, I. Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(12)DOI:10.3390/antibiotics13121138. PMID:39766528. IF:4.600(Q1/2D).

21/02/2026 Adequacy of the Type of Venous Catheter to the Drug Type and Duration of Treatment: A Cross-Sectional Study

Moreno-Rubio, E, Pérez-López, C, Carmezim, J, Blancas-Altabella, D, Simonetti, AF, Sanchez, SS, Rodríguez-Molinero, A. Adequacy of the Type of Venous Catheter to the Drug Type and Duration of Treatment: A Cross-Sectional Study. Nursing Reports. 2026; 16(2)DOI:10.3390/nursrep16020076. PMID:41745901. IF:(Q/D).

01/08/2024 Characterization of white matter hyperintensities in Down syndrome

Morcillo-Nieto, AO, Zsadanyi, SE, Arriola-Infante, JE, Carmona-Iragui, M, Montal, V, Pegueroles, J, Aranha, MR, Vaque-Alcazar, L, Padilla, C, Benejam, B, Videla, L, Barroeta, I, Fernandez, S, Altuna, M, Gimenez, S, Gonzalez-Ortiz, S, Bargallo, N, Ribas, L, Arranz, J, Torres, S, Iulita, MF, Belbin, O, Camacho, V, Alcolea, D, Lleo, A, Fortea, J, Bejanin, A. Characterization of white matter hyperintensities in Down syndrome. ALZHEIMERS & DEMENTIA. 2024; 20(9)DOI:10.1002/alz.14146. PMID:39087352. IF:11.100(Q1/1D).

26/03/2024 Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

Ospina, AV, Nadal, SB, de la Cruz, JLCC, Larriba, JLG, Vidueira, IM, Sureda, BM, Nadal, E, Trancho, FH, Kindelan, AA, Morillo, E, Caro, RB, Barrera, JB, de Juan, VC, Rubio, JC, de Castro, J, Ramos, AC, Dols, MC, Gomez, M, Almanzar, S, Campelo, RG, Molla, AI, Sarceda, JRJ, Maestre, UJ, Castro, RL, Majem, M, Martinez-Marti, A, Tellez, EM, Lorente, DS, Provencio, M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03382-y. PMID:38530556. IF:2.500(Q3/6D).

01/03/2026 Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.

Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).

01/04/2026 Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial

Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).

26/03/2026 Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants

Garcia, AM, Rezqallah-Arón, A, Duran-Lozano, L, López-Fernández, A, Darder, E, Alfonso, R, Cartró, M, Cruellas, M, Reig-Jané, J, Roqué, A, Tuset, N, Cajal, TRY, Brunet, J, Balmaña, J. Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants. EUROPEAN JOURNAL OF CANCER. 2026; 237DOI:10.1016/j.ejca.2026.116560. PMID:. IF:7.100(Q1/2D).

01/03/2026 Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.

Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).

12/03/2026 IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort

Martin-Broto, J, Strauss, SJ, Palmerini, E, Valverde, C, Sebio, A, Redondo, A, Stacchiotti, S, Grignani, G, Aliberti, S, Diaz-Beveridge, R, Billalabeitia, EG, Cruz, J, Carrasco-Garcia, I, Ibrahim, T, Diaz-Martin, J, Salguero-Aranda, C, Gutierrez, A, Mayordomo-Aranda, E, Ramos, R, Merino, J, Collini, P, Tirabosco, R, Bague, S, Romagosa, C, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer Communications. 2026; 46DOI:10.34133/cancomm.0015. PMID:41836677. IF:24.900(Q1/1D).

01/04/2026 Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy

Holgado, A, Llansana, A, Vázquez, C, Gallego, O, Aguado, M, Valero, C, León, X. Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy. ORAL ONCOLOGY. 2026; 175DOI:10.1016/j.oraloncology.2026.107903. PMID:41722172. IF:3.900(Q1/2D).

01/03/2026 SEOM-AEEMT consensus on occupational cancer and cancer-associated disability

Mezquita, L, Vicente-Herrero, MT, Cruz, P, de la Torre, MVRI, Hidalgo-Coloma, J, Garcia, LC, Gallego, O, Calvo, A, Martinez, K, Perez-Altozano, J, Molina, R, Garcia-Pardo, M, Gutierrez-Sainz, L, Moreno-Atahonero, E, Ore-Arce, M, Serrano, C, Terradillos-Garcia, MJ, Valero, MR, Reinoso-Barbero, L, Rodriguez, CA, Calvo-Cerrada, B. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04037-2. PMID:40956506. IF:2.500(Q3/6D).

09/03/2026 Multidisciplinary Treatment of Inguinoscrotal Sarcomas: Analysis of 39 Cases Treated by Surgical Approach

Samsó, RH, Cabré, LC, Abós, SG, Solerdelcoll, MS, Majercakova, K, García, AS, Alegria, IG, Garrido, MF, Duarte, AM, López, JAG. Multidisciplinary Treatment of Inguinoscrotal Sarcomas: Analysis of 39 Cases Treated by Surgical Approach. Cancers. 2026; 18(5)DOI:10.3390/cancers18050876. PMID:41827809. IF:4.400(Q2/3D).

16/03/2026 TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances

Portu, M, Balsa, M, Cotaina, M, Anguera, G, del Muro, XG, Algaba, F, Maroto, P. TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. Cancers. 2026; 18(6)DOI:10.3390/cancers18060958. PMID:41899560. IF:4.400(Q2/3D).

01/01/2025 Precision targeting of CXCR4+leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model.

Garcia-Leon, Annabel, Mendoza, Julian I, Rueda, Ariana, Alba-Castellon, Lorena, Nomdedeu, Josep F, Gallardo, Alberto, Sierra, Jorge, Garrido, Ana, Vazquez, Esther, Villaverde, Antonio, Mangues, Ramon, Unzueta, Ugutz, Casanova, Isolda. Precision targeting of CXCR4+leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025; 192DOI:10.1016/j.biopha.2025.118573. PMID:. IF:(Q/D).

01/09/2024 Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles

Parladé, E, García-Leon, A, Voltà-Durán, E, Unzueta, U, Mangues, R, Casanova, I, Villaverde, A, Váquez, E. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2024; 202DOI:10.1016/j.ejpb.2024.114410. PMID:39004320. IF:4.300(Q1/2D).

01/12/2022 Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (vol 101, 2231, 2022)

Triguero, A, Pedraza, A, Perez-Encinas, M, Mata-Vazquez, MI, Velez, P, Fox, L, Gomez-Calafat, M, Garcia-Delgado, R, Gasior, M, Ferrer-Marin, F, Garcia-Gutierrez, V, Angona, A, Gomez-Casares, MT, Cuevas, B, Martinez, C, Perez, R, Raya, JM, Guerrero, L, Murillo, I, Bellosillo, B, Hernandez-Boluda, JC, Sanz, C, Alvarez-Larran, A. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (vol 101, 2231, 2022). ANNALS OF HEMATOLOGY. 2022; 101(12)DOI:10.1007/s00277-022-05005-4. PMID:36264368. IF:3.500(Q2/5D).

01/01/2026 Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular

Fernández-Luis, S, Bermúdez, A, San Segundo, LY, González, MB, Asensio, SM, Esquirol, A, García-Cadenas, I, Pascual, MJ, Herruzo, B, Salas, MQ, Alburquerque-Prieto, C, Viguria-Alegría, MC, Pérez, A, Hernani, R, Mas, MH, Villalba, M, Calvo, CM, Fabbri, N, González-Rodriguez, AP, Bailén, R, Tomás, LG, Maño, LG, Salinas, AS, Calbacho, M, Bento, L, Balari, AS. Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular. TRANSPLANTATION. 2026; 110(1)DOI:10.1097/TP.0000000000005446. PMID:40524321. IF:5.000(Q1/1D).

01/12/2024 Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study

Abrisqueta-Costa, P, García-Marco, JA, Gutiérrez, A, Hernández-Rivas, JA, Andreu-Lapiedra, R, Arguello-Tomas, M, Leiva-Farré, C, López-Roda, MD, Callejo-Mellén, A, Alvarez-García, E, Loscertales, J. Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study. Cancers. 2024; 16(23)DOI:10.3390/cancers16234004. PMID:39682190. IF:4.400(Q2/3D).

01/01/2026 Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT

Nagler, A, Galimard, JE, Kayser, S, Kulagin, A, Blaise, D, Parovichnikova, E, Versluis, J, Itäla-Remes, M, Choi, G, Bufarull, RM, Sica, S, Roeven, MWH, von dem Borne, P, Bazarbachi, A, Sanz, J, Mohty, M, Ciceri, F. Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT. BONE MARROW TRANSPLANTATION. 2026; 61(1)DOI:10.1038/s41409-025-02726-8. PMID:41109900. IF:5.200(Q1/1D).

07/02/2024 Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis (vol 20, pg 917, 2018)

Madaro, L, Passafaro, M, Sala, D, Etxaniz, U, Lugarini, F, Proietti, D, Alfonsi, MV, Nicoletti, C, Gatto, S, De Bardi, M, Rojas-Garcia, R, Giordani, L, Marinelli, S, Pagliarini, V, Sette, C, Sacco, A, Puri, PL. Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis (vol 20, pg 917, 2018). NATURE CELL BIOLOGY. 2024; 26(3)DOI:10.1038/s41556-024-01365-3. PMID:38326555. IF:19.100(Q1/1D).

09/07/2024 Single cell RNA sequencing of human FAPs reveals different functional stages in Duchenne muscular dystrophy

Fernández-Simón, E, Piñol-Jurado, P, Gokul-Nath, R, Unsworth, A, Alonso-Pérez, J, Schiava, M, Nascimento, A, Tasca, G, Queen, R, Cox, D, Suarez-Calvet, X, Díaz-Manera, J. Single cell RNA sequencing of human FAPs reveals different functional stages in Duchenne muscular dystrophy. Frontiers in Cell and Developmental Biology. 2024; 12DOI:10.3389/fcell.2024.1399319. PMID:39045456. IF:4.300(Q1/1D).

01/04/2026 Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients

Ganoza, CA, Westenberger, A, Paul, JJ, Curado, F, Rennecke, J, Mannepalli, S, Zonic, E, Saravanakumar, D, Paknia, O, Al-Ali, R, Laabs, B, Csoti, I, Valzania, F, Vandenberghe, W, Reetz, K, Afshari, M, Hassin-Baer, S, Fonoff, ET, Gruber, D, de Rosa, A, Musacchio, T, Aguiar, PD, Negrotti, A, Tumas, V, Gomez-Esteban, JC, Gurevich, T, Pavese, N, Kulisevsky, J, Sammler, E, Klein, C, Bauer, P, Beetz, C. Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients. MOVEMENT DISORDERS. 2026; 41(4)DOI:10.1002/mds.70161. PMID:41439479. IF:7.600(Q1/1D).

01/06/2026 Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation

Stocchi, F, Knecht, M, Marjanovic, I, Wach, A, Kopra, J, Kulisevsky, J. Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation. Neurology and Therapy. 2026; 15(3)DOI:10.1007/s40120-026-00898-z. PMID:41724884. IF:4.800(Q1/2D).

31/01/2026 Ten-year population-based assessment of multimorbidity burden progression in a regional cohort of 5.5 million adults

Valero-Bover, D, Monterde, D, Carot-Sans, G, Vela, E, González-Colom, R, Roca, J, Pontes, C, Michelena, X, Nogueras, MM, Aparicio, P, Corrales, I, Biec, T, Cano, I, Piera-Jiménez, J. Ten-year population-based assessment of multimorbidity burden progression in a regional cohort of 5.5 million adults. npj Digital Medicine. 2026; 9(1)DOI:10.1038/s41746-026-02395-x. PMID:41620560. IF:15.100(Q1/1D).